Skip To Main Content
Joaquina Baranda on Muck Rack

Joaquina Baranda

As seen in: Nature, Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Joaquina

Contact Joaquina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Glioblastoma, IDH- wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

|
By Joaquina Baranda, Wei Zhang, Mohammad Haeri, Brian Milligan, Tolga Tuncer, Anaya Dewey
| Frontiers
Abstract A woman, in her mid-50s, presented with headache, confusion, and unstable gait due to a large right parietal mass subsequently diagnosed histologically as glioblastoma, IDH-wildtype, CNS WHO Grade 4 with an unmethylated MGMT promoter. Next-generation sequencing revealed a rare gene fusion involving myocyte enhancer factor 2D and neurotrophic receptor tyrosine kinase 1 (MEF2D-NTRK1), informing our therapeutic approach.
Open in Who Shared Issue with article?

Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort | Nature Communications

|
By Anwaar Saeed, Ayah Al-Bzour, Weijing Sun, Stephen Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Hassan Abushukair, Andrew Godwin, Joaquina Baranda
| Nature Verified
Abstract CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS tumors. Primary endpoint was met with ORR of 27.6% (95% CI 12.7-47.2%). Secondary endpoints of 4-month PFS rate was 44.83% (95% CI 26.5-64.3%); and median OS was 9.1 months (95% CI 5.8-20.2). Grade≥3 TRAE occurred in 39%.
Open in Who Shared Issue with article?
See all 2 articles